Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...
A settlement has been reached in the legal battle between NASCAR and two race teams over antitrust allegations.
Footprints of The Frontier on MSN
Who were the seven Cheyenne - and why were they put on trial?
The murder trial of the Seven Cheyenne stands as one of the most dramatic and complex legal battles in the history of the Old West. After a violent incident sparked a regional manhunt, the Cheyenne ...
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing ...
As a work of reportage, Off the Scales does a wonderful job of explaining the origins of Ozempic and other GLP-1 drugs and ...
I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...
The case, filed in the Court of International Trade, argues that Trump used an emergency-powers law to impose tariffs on ...
Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...
Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.
Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback